Clinical relevance of point mutations in the 23S rRNA gene in Helicobacter pylori eradication
Authors:
Open Access
- 1 August 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 97 (33) , e11835
Abstract
Clarithromycin-based triple therapy is prescribed worldwide for Helicobacter pylori eradication. However, increases in the clarithromycin resistance of H pylori are thought to be responsible for eradication failure. Here, we studied whether point mutations in domain V of the 23S rRNA gene can affect H pylori eradication failure in a prospective, open-label, observational study. Of the 755 enrolled patients, 299 patients (39.6%) had positive Campylobacter-like organism (CLO) tests. DNA sequencing analysis of H pylori 23S rRNA in 295 patients revealed that 2143G was the most frequent point mutation (24.7% of patients), followed by the 2182T mutation (11.5%). The overall eradication failure rate was 20.9% (42/201) in clarithromycin-based triple therapy. Patients with the 2143G had an approximately 60% eradication failure rate, which suggested that 2143G was a high-risk genotype for eradication failure. Patients with the 2182C genotype without 2143G had an 8.7% failure rate, and patients without 2143G or 2182C had only a 4.3% failure rate. The presence of 2143G, which was associated with previous eradication history and female sex, was an independent risk factor for eradication failure. In conclusion, the 2143G point mutation in the 23S rRNA of H pylori was an independent risk factor for eradication failure in clarithromycin-based triple therapy. Personalized tailored therapy based on the genotypes of 23S rRNA can increase eradication success rates in H pylori infections.Keywords
This publication has 29 references indexed in Scilit:
- Treatment of Helicobacter pylori infection 2016Helicobacter, 2016
- Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USADigestive Diseases and Sciences, 2016
- Clarithromycin-Based Standard Triple Therapy Can Still Be Effective forHelicobacter pyloriEradication in Some Parts of the KoreaJournal of Korean Medical Science, 2014
- Update on triple therapy for eradication of Helicobacter pylori: current status of the artClinical and Experimental Gastroenterology, 2012
- Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enoughAlimentary Pharmacology & Therapeutics, 2011
- Change in Antibiotic Resistance of Helicobacter pylori Strains and the Effect of A2143G Point Mutation of 23S rRNA on the Eradication of H. pylori in a Single Center of KoreaJournal of Clinical Gastroenterology, 2010
- Helicobacter pyloriInfectionNew England Journal of Medicine, 2010
- Epidemiology of Helicobacter pylori infection and gastric cancer in AsiaJournal of Gastroenterology and Hepatology, 2010
- Helicobacter pyloriDetection and Antimicrobial Susceptibility TestingClinical Microbiology Reviews, 2007
- Distribution of Antibiotic MICs for Helicobacter pylori Strains over a 16-Year Period in Patients from Seoul, South KoreaAntimicrobial Agents and Chemotherapy, 2004